Hepatic Hilar Lymph Node Resection in Cytoreductive Surgery for Advanced Ovarian Cancer: A Necessity or Not?

References

• Cook SA, Tinker AV. PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs. 2019;33(3):255–273. doi:10.1007/s40259-019-00347-430895466
   PubMed Web of Science ®Google Scholar
• Moschetta M, Boussios S, Rassy E, Samartzis EP, Funingana G, Uccello M. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann Transl Med. 2020;8(24):1710. doi:10.21037/atm-20-168333490222
   PubMed Web of Science ®Google Scholar
• Boussios S, Moschetta M, Zarkavelis G, Papadaki A, Kefas A, Tatsi K. Ovarian sex-cord stromal tumours and small cell tumours: pathological, genetic and management aspects. Crit Rev Oncol Hematol. 2017;120:43–51. doi:10.1016/j.critrevonc.2017.10.00729198337
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191–226. doi:10.6004/jnccn.2021.000733545690
   PubMed Web of Science ®Google Scholar
• Martinez A, Pomel C, Mery E, Querleu D, Gladieff L, Ferron G. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2011;121(2):258–263. doi:10.1016/j.ygyno.2010.12.32821295334
   PubMed Web of Science ®Google Scholar
• Raspagliesi F, Ditto A, Martinelli F, Haeusler E, Lorusso D. Advanced ovarian cancer: omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor. Gynecol Oncol. 2013;129(1):92–96. doi:10.1016/j.ygyno.2013.01.02423385151
   PubMed Web of Science ®Google Scholar
• Tozzi R, Traill Z, Garruto Campanile R, et al. Porta hepatis peritonectomy and hepato–celiac lymphadenectomy in patients with stage IIIC–IV ovarian cancer: diagnostic pathway, surgical technique and outcomes. Gynecol Oncol. 2016;143(1):35–39. doi:10.1016/j.ygyno.2016.08.23227519966
   PubMed Web of Science ®Google Scholar
• Ramesh Babu CS, Sharma M. Biliary tract anatomy and its relationship with venous drainage. J Clin Exp Hepatol. 2014;4(Suppl 1):S18–S26. doi:10.1016/j.jceh.2013.05.00225755590
   PubMedGoogle Scholar
• Li J, Zhou MH, Ma WJ, Li FY, Deng YL. Extended lymphadenectomy in hilar cholangiocarcinoma: what it will bring? World J Gastroenterol. 2020;26(24):3318–3325. doi:10.3748/wjg.v26.i24.331832655260
   PubMed Web of Science ®Google Scholar
• Song YJ, Lim MC, Kang S, et al. Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer. Gynecol Oncol. 2011;121(2):253–257. doi:10.1016/j.ygyno.2010.12.35021277009
   PubMed Web of Science ®Google Scholar
• Martínez A, Pomel C, Filleron T, et al. Prognostic relevance of celiac lymph node involvement in ovarian cancer. Int J Gynecol Cancer. 2014;24(1):48–53. doi:10.1097/IGC.000000000000004124356411
   PubMed Web of Science ®Google Scholar
• Gallotta V, Ferrandina G, Vizzielli G, et al. Hepatoceliac lymph node involvement in advanced ovarian cancer patients: prognostic role and clinical considerations. Ann Surg Oncol. 2017;24(11):3413–3421. doi:10.1245/s10434-017-6005-128718034
   PubMed Web of Science ®Google Scholar
• Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–104.1234624
   PubMedGoogle Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–1259. doi:10.1200/JCO.2002.20.5.124811870167
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006;100(2):283–287. doi:10.1016/j.ygyno.2005.08.02716182350
   PubMed Web of Science ®Google Scholar
• Fu X, Ma Q, Li J. The risk factors of retroperitoneal lymph node metastasis in ovarian cancer and the observation of MRI and CT imaging characteristics. Chin J CT MRI. 2020;18(9):134–138.
   Google Scholar
• Yu Z, Meng C, Zhao C, Chen B, Zhao X, Li W. Assessment of ovarian cancer lymph node metastasis based on CT image texture analysis technique. Mod Oncol. 2020;28(18):3222–3226.
   Google Scholar
• Kasper SM, Dueholm M, Marinovskij E, Blaakær J. Imaging diagnostics in ovarian cancer: magnetic resonance imaging and a scoring system guiding choice of primary treatment. Eur J Obstet Gynecol Reprod Biol. 2017;210:83–89. doi:10.1016/j.ejogrb.2016.10.03427984747
   PubMed Web of Science ®Google Scholar
• Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol. 2016;206(6):1351–1360. doi:10.2214/AJR.15.1519927042752
   PubMed Web of Science ®Google Scholar
• Kemppainen J, Hynninen J, Virtanen J, Seppänen M. PET/CT for evaluation of ovarian cancer. Semin Nucl Med. 2019;49(6):484–492. doi:10.1053/j.semnuclmed.2019.06.01031630732
   PubMed Web of Science ®Google Scholar
• Khiewvan B, Torigian DA, Emamzadehfard S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1079–1091. doi:10.1007/s00259-017-3638-z28180966
   PubMed Web of Science ®Google Scholar
• Tato-Varela S, Kuhn W. Impact of retroperitoneal lymph node dissection in ovarian cancer - time for paradigm shift? Horm Mol Biol Clin Investig. 2019;41(3). doi:10.1515/hmbci-2019-0020
   PubMed Web of Science ®Google Scholar
• Angeles MA, Ferron G, Cabarrou B, et al. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer. Eur J Surg Oncol. 2019;45(8):1410–1416. doi:10.1016/j.ejso.2019.02.01830857876
   PubMed Web of Science ®Google Scholar